News Background

Oxford, UK – 07 April 2020. OGT, A Sysmex Group Company, announces the addition of accurate detection capabilities for translocations and difficult-to-sequence partial tandem duplications (PTDs) in its popular myPanel™ customizable SureSeq™ NGS panels. This latest update is, for example, beneficial to researchers investigating myeloid disorders like chronic myeloid leukemia (CML), myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML), now enabled with BCR-ABL fusion gene and KMT2A-PTD detection.

OGT already offers researchers the rapid and reliable detection of a complete set of genetic aberrations, including single nucleotide variations (SNVs), insertions/ deletions (indels), internal tandem duplications (ITD), copy number variations (CNVs), and loss of heterozygosity (LOH) — even at low-frequencies.

Until now, a lack of sensitive and reliable NGS solutions has meant that researchers often needed to employ multiple methods to accurately characterize structural aberrations in their samples. To address this, OGT recently added somatic CNV detection to their NGS portfolio, with the launch of their SureSeq CLL + CNV Panel. Responding to latest research findings, OGT has leveraged its long heritage and expertise in hybridization, design capability and bioinformatics to enable PTD and translocation detection in a single, reliable assay.

The expanded content enables OGT SureSeq myPanel™ custom panels to be customized to include the BCR-ABL gene fusion, resulting from a translocation of chromosome 9 and 22 generating the Philadelphia chromosome — the hallmark of chronic myeloid leukemia (CML). Importantly, in addition to detecting this translocation, OGT’s complimentary and easy-to-use Interpret software can detect translocation events anywhere in the genome. Thanks to OGT’s renowned bioinformatics expertise, the software is able to agnostically screen for split-reads, reporting translocation partners in any genomic location.

In addition, building on OGT’s already excellent coverage uniformity of other difficult-to-sequence genes such as CEBPA, and genes with challenging ITDs—for example FLT3—PTDs in AML can now also be detected, including those in the KMT2A (MLL) gene. Researchers can choose to customize content and include KMT2A-PTD detection to make their SureSeq panels more all-encompassing.

These new content and detection capabilities represent a substantial advancement for researchers, as Emma Shipstone, Executive VP Marketing at OGT, highlights: “We’re excited to bring the expanded customizable SureSeq™ content and Interpret NGS analysis software capabilities to market—helping researchers get to the information they need in the quickest, most reliable way possible. OGT has a long heritage of excellence in hybridization-based solutions that encompasses our unrivaled NGS design capabilities and bioinformatics expertise. This enables us to provide confident solutions for hard-to-sequence regions, delivering unparalleled coverage uniformity and pushing the boundaries of NGS panels and analysis software to answer the call for comprehensive sequencing solutions. NGS is a key future technology for OGT as part of the Sysmex Group. We are committed to continuing to meet and exceed the needs of researchers, now and in the future; there are exciting possibilities and development plans in the pipeline.”

OGT’s SureSeq NGS portfolio delivers comprehensive sequencing solutions, from wet-lab to computational, including library preparation kits, customizable panels and complimentary Interpret NGS Analysis software. The company’s exceptional coverage uniformity, trusted data analysis software and renowned customer support enable researchers to simplify workflows with reliable, tailored panels that accurately detect all relevant genomic aberrations in a single, comprehensive assay.

Related content

  • Share

You might also be interested in

OGT expands NGS cancer panel offering Listing Image

OGT expands NGS cancer panel offering

03 Nov 2020

Launch of two NGS panels enables comprehensive detection of genetic abnormalities involved in breast and ovarian cancer, and myeloid disorders.

OGT's NGS panels to be featured in user workshop at AMP 2020 Listing Image

OGT's NGS panels to be featured in user workshop at AMP 2020

09 Nov 2020

In the workshop users will explain how OGT’s SureSeq™ NGS panels can increase throughput and save time and cost in the detection of a wide variety of aberrations.

OGT unveils reliable somatic CNV detection for CLL with new NGS panel Listing Image

OGT unveils reliable somatic CNV detection for CLL with new NGS panel

13 Jan 2020

SureSeq™ CLL + CNV - comprehensive CLL genomic profiling from a single assay.

All News
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter